Communicators

Medigene AG: Medigene announces participation at six upcoming investor and scientific conferences

Business news for the stock market

Planegg (19.01.2018) - Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at six upcoming investor and scientific conferences:

Precision Medicine World Conference (PMWC) 2018

Date: 22 - 24 January 2018

Location: Mountain View, CA, USA

Dr. Kai Pinkernell, Chief Medical Officer of Medigene, will give a presentation during the PMWC 2018 Immunotherapy Showcase on 23 January at 2 pm on the topic "Using cutting-edge technologies to develop TCR-based immunotherapies".

ASCO-SITC Clinical Immuno-Oncology Symposium

Date: 25 - 27 January 2018

Location: San Francisco, CA, USA

BioCapital Europe

Date: 6 February 2018

Location: Amsterdam, Netherlands

Julia Hofmann, Head of Public & Investor Relations at Medigene, will hold a company presentation on 6 February at 4.40 pm.

Immuno-Oncology 360°

Date: 7 - 9 February 2018

Location: New York, USA

Dr. Thomas Taapken, CFO of Medigene, takes part in the discussion panel entitled "Raising Money in the Current Climate" on 9 February at 2 pm.

CAR-TCR Summit Europe 2018

Date: 20 - 22 February 2018

Location: London, UK

Prof. Dolores Schendel, CEO and CSO of Medigene, will hold a company presentation on 22 February.

ODDO - 11th German Conference

Date: 21 - 22 February 2018

Location: Frankfurt; Germany

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG

Julia Hofmann, Dr. Robert Mayer

Tel.: +49 - 89 - 20 00 33 - 33 01,

email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

emitter: Medigene AG

address: Lochhamer Straße 11, 82152 Planegg

country: Germany

contact person: Medigene PR/IR

phone: +49 89 2000 33 3301

e-mail: investor@medigene.com

website: www.medigene.de

ISIN(s): DE000A1X3W00 (share)

stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate